Fly News Breaks for March 10, 2015
MACK, VSTM, OMED, ZIOP
Mar 10, 2015 | 05:23 EDT
Mizuho analyst Peter Lawson downgraded Ziopharm (ZIOP) to Neutral citing valuation with the stock near his $14 price target. Lawson believes the risk/reward is more favorable for other oncology plays like OncoMed (OMED), Verastem (VSTM) and Merrimack (MACK).
News For ZIOP;OMED;VSTM;MACK From the Last 2 Days
There are no results for your query ZIOP;OMED;VSTM;MACK